From: Early-onset neonatal sepsis and antibiotic use in Indonesia: a descriptive, cross-sectional study
Antibiotics | EOS | Non-EOS (n = 797) | ||
---|---|---|---|---|
Culture proven (n = 83) | Culture negative (n = 112) | Absence of culture facility (n = 47) | ||
Initial antibiotics | ||||
 Ampicillin / Amoxicillin | 76 (91.6%) | 47 (42.0%) | 3 (6.4%) | 156 (19.6%) |
 Gentamicin | 17 (20.5%) | 55 (49.1%) | 10 (21.3%) | 457 (57.3%) |
 Amikacin | 78 (94.0%) | 73 (65.2%) | 2 (4.3%) | 229 (28.7%) |
 Third-generation cephalosporin | 27 (32.5%) | 26 (23.2%) | 41 (87.2%) | 181 (22.7%) |
Overall antibiotics | ||||
 Ampicillin / Amoxicillin | 76 (91.6%) | 48 (42.9%) | 3 (6.4%) | 157 (19.7%) |
 Penicillin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
 Gentamicin | 19 (22.9%) | 55 (49.1%) | 10 (21.3%) | 458 (57.5%) |
 Netilmicin | 39 (47.0%) | 8 (7.1%) | 0 (0.0%) | 12 (1.5%) |
 Amikacin | 82 (98.8%) | 74 (66.1%) | 2 (4.3%) | 229 (28.7%) |
 Ampicillin-Sulbactam | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
 Amoxicillin-Clavulanic acid | 3 (3.6%) | 45 (40.2%) | 0 (0.0%) | 398 (49.9%) |
 Piperacillin-tazobactam | 3 (3.6%) | 28 (25%) | 0 (0.0%) | 93 (11.4%) |
 Imipenem | 4 (4.8%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) |
 Meropenem | 20 (24.1%) | 9 (8.0%) | 0 (0.0%) | 16 (2.0%) |
 Doripenem | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (0.4%) |
 Third-generation cephalosporin | 68 (81.9%) | 28 (25.0%) | 41 (87.2%) | 182 (22.8%) |
 Fourth-generation cephalosporin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (0.3%) |
 Ciprofloxacin | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
 Vancomycin | 1 (1.2%) | 0 (0.0%) | 3 (6.4%) | 3 (0.4%) |
 Metronidazole | 11 (13.3%) | 5 (4.5%) | 0 (0.0%) | 15 (1.9%) |